Key Insights

Highlights

Success Rate

84% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

4.4%

5 terminated out of 113 trials

Success Rate

83.9%

-2.6% vs benchmark

Late-Stage Pipeline

11%

12 trials in Phase 3/4

Results Transparency

38%

10 of 26 completed with results

Key Signals

10 with results84% success

Data Visualizations

Phase Distribution

96Total
Not Applicable (20)
Early P 1 (9)
P 1 (42)
P 2 (13)
P 3 (4)
P 4 (8)

Trial Status

Recruiting50
Completed26
Not Yet Recruiting13
Active Not Recruiting7
Unknown6
Terminated5

Trial Success Rate

83.9%

Benchmark: 86.5%

Based on 26 completed trials

Clinical Trials (113)

Showing 20 of 20 trials
NCT05352919Phase 3Enrolling By InvitationPrimary

An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT07175285RecruitingPrimary

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

NCT05000216Phase 2Terminated

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT06626945CompletedPrimary

AZAHAR Study To Describe Anifrolumab in a Real-World Setting

NCT06032923Phase 1RecruitingPrimary

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

NCT05567198RecruitingPrimary

Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires

NCT06335979Phase 1RecruitingPrimary

An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

NCT07611747Phase 4Recruiting

Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)

NCT06314282RecruitingPrimary

INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use

NCT06647069Phase 1RecruitingPrimary

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

NCT06308978Phase 1Recruiting

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

NCT03656562Phase 2CompletedPrimary

Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients

NCT07575347Not Yet Recruiting

Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)

NCT07332481Phase 3RecruitingPrimary

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

NCT07085676Phase 1Recruiting

Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

NCT07555626Not ApplicableNot Yet RecruitingPrimary

Mediterranean Diet and Gut Microbiota in Children With Systemic Lupus Erythematosus

NCT07425730RecruitingPrimary

Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric Lupus

NCT07544225Phase 1Not Yet Recruiting

Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases

NCT07538154Phase 1Not Yet RecruitingPrimary

A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus

NCT07087912Phase 4Recruiting

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

Scroll to load more

Research Network

Activity Timeline